In the media

the FDA had informed the company that it would not need to redo safety trials if all of the vaccine ingredients were the same and only the viral sequence was changed.

It’s likely the company’s drug candidate will act as a second-generation vaccine that could improve upon and supplement products already on the market.

Andrey Zarur, CEO of GreenLight Biosciences, wrote for STAT about the Covid-19 vaccine supply chain.

GreenLight Biosciences spoke to the Financial Times about making sure that any vaccine is new variant ready for Covid-19.

GreenLight Biosciences spoke to the Financial Times about the vaccine supply issues for the Covid-19 vaccine

GreenLight Biosciences spoke to Mail Online about the vaccine supply issues in rolling out the Covid-19 vaccine

GreenLight Biosciences spoke to Technology Review about the vaccine ingredients for Pfizer’s Covid-19 vaccine, including messenger RNA.

GreenLight CEO, Andrey Zarur, spoke to the Financial Times about the Covid-19 vaccine manufacturing delays, with the hold up leaving the UK with fewer vaccines dosages than it had hoped.

GreenLight CEO, Andrey Zarur, spoke to Investor’s Business Daily about the Covid-19 vaccine manufacturing challenge, with billions around the world in need.

With manufacturing capacity in the news following the announcement of successful Covid-19 vaccine trials, Greenlight Biosciences CEO Andrey Zarur explains to Biospace the potential of the messenger RNA vaccine